Benefits
Allergic rhinitis symptom relief
In the one published human trial (Badar 2005, PMID 15619563), a randomized, double-blind, placebo-controlled study in 75 adults with diagnosed allergic rhinitis, participants taking Tinospora extract (300 mg/day for 8 weeks) reported greater reductions in nasal discharge, sneezing, nasal obstruction, and nasal itching than those taking placebo, with 83% versus 17% showing improvement. This is a single, small, unreplicated trial conducted in a diagnosed disease population — it does not establish that the extract treats, cures, or prevents allergic rhinitis, and results in that setting may not apply to healthy people.
Immune system modulation
In laboratory and animal studies summarized in a peer-reviewed narrative review (Yates 2022, PMID 33480818), Tinospora polysaccharides activated macrophages and dendritic cells, increased NK cell activity, and shifted Th1/Th2 immune balance — shifting from the Th2-dominant state that drives allergic responses toward a more balanced immune profile. Used traditionally for recurrent infections and immune deficiency states.
Anti-inflammatory activity
Tinospora alkaloids and glycosides inhibit NF-κB activation, COX-2 expression, and prostaglandin production. The arthritis evidence cited here (Sannegowda 2015, PMID 26467057) is an animal study, not a human trial: T. cordifolia extract suppressed pro-inflammatory cytokines and joint damage in a rodent model of autoimmune arthritis. No human trial measuring inflammatory markers with T. cordifolia is cited on this page, so these findings remain preclinical.
Blood sugar regulation
Traditional use and preclinical work have explored T. cordifolia in relation to glucose metabolism, with proposed mechanisms including alpha-glucosidase inhibition and effects on insulin secretion and peripheral glucose utilization. Important limitation: no human glucose or diabetes trial is among the references cited on this page, so this remains an unverified mechanism-level rationale rather than a demonstrated effect. Diabetes is a medical condition requiring professional care, and this ingredient is not a treatment for it.
Adaptogenic and neuroprotective effects
T. cordifolia is described in Ayurvedic tradition as a rasayana used for stamina and resilience, and laboratory and animal work has examined effects on cortisol signaling and on neurons under oxidative or excitotoxic stress. No human trial of stress, fatigue, or cognition with T. cordifolia is cited on this page, so this section reflects traditional use and preclinical findings only.
Mechanism of action
Macrophage and NK cell activation
Tinospora polysaccharides bind pattern recognition receptors (TLR-2, TLR-4, Dectin-1) on macrophages, triggering MyD88-dependent NF-κB activation and cytokine production. This innate immune priming increases NK cell cytotoxicity and accelerates pathogen clearance.
Th2-to-Th1 immune shifting
T. cordifolia extracts shift the cytokine balance from Th2 (allergic, IL-4, IL-5, IL-13-dominant) to Th1 (cellular, IFN-γ, IL-12-dominant) immune responses — a pattern proposed as relevant to allergic-type immune responses. These are preclinical observations; no human trial cited here evaluated asthma or atopic dermatitis.
Alpha-glucosidase inhibition
Tinospora alkaloids and polysaccharides inhibit intestinal alpha-glucosidase enzyme activity, slowing carbohydrate digestion and glucose absorption — a mechanism observed in laboratory assays. This is a preclinical finding only; no human data cited on this page demonstrate a glucose-lowering effect, and the ingredient is not a substitute for prescribed medication.
Clinical trials
Randomized, double-blind, placebo-controlled trial of Tinofend® (300 mg/day) vs. placebo in 75 patients with allergic rhinitis for 8 weeks.
75 adults with confirmed allergic rhinitis. 8-week intervention.
83% of Tinofend® patients showed clinically meaningful improvement in total nasal symptom score vs. 17% placebo. Significant reductions in sneezing, discharge, obstruction, and nasal pruritis. Tolerability was reported as good over the 8-week period. This is a single, small, unreplicated trial in a diagnosed disease population and is the only human trial of Tinospora cited on this page; larger independent replication has not been published.